Rafael Holdings at Guggenheim conference touts npc drug despite trial miss
On 09 November 2026, Rafael Holdings (RFL) addressed its prospects for the drug remibetadex at the 3rd Annual Guggenheim Healthcare Innovation Conference. The company announced the successful completion of a Phase III study, an FDA filing, and a potential commercial strategy for the treatment of Niemann-Pick type C (NPC), a rare genetic disorder with both neurological and visceral symptoms.
Despite the trial falling short of its primary endpoint, Rafael maintains that the pre-specified covariate analysis and other data support the filing. With just over $22 million in cash at the end of July 2025, the company anticipates enduring until the FDA's decision window in December 2025. The stock, currently trading at $1.09, has seen a 4.81% increase from the previous close of $1.04.
However, it is trading at 10% above its 52-week low, reflecting a challenging year for shareholders who have experienced a 19% decrease over the past year and an 18.75% decline in just six months.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
